RecruitingHaematological MalignancyAcute Myeloid LeukemiaNon Hodgkin Lymphoma
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Eligible age
18+ yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Sponsor: CellCentric Ltd.
You may qualify if…
- ✓ Provision of consent
- ✓ ECOG performance status 0-2
- ✓ Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML)
- ✓ Must have previously received standard therapy
- ✓ Adequate organ function
You may not qualify if…
- ✕ Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose
- ✕ Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment
- ✕ Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
- ✕ Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment
- ✕ Patients should discontinue statins prior to starting study treatment
- ✕ CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
- ✕ Any unresolved reversible toxicities from prior therapy \>CTCAE grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy)
- ✕ Any evidence of severe or uncontrolled systemic diseases
Where it's recruiting
Source: ClinicalTrials.gov · NCT04068597 · last updated 2026-06-24